Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Profit After Tax (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Profit After Tax for 4 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax fell 7.28% to -$2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$8.0 million, a 0.65% decrease, with the full-year FY2024 number at -$7.9 million, down 111.04% from a year prior.
  • Profit After Tax was -$2.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, down from -$1.7 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $4.2 million in Q3 2023 to a low of -$4.2 million in Q2 2024.
  • A 4-year average of -$1.6 million and a median of -$2.0 million in 2023 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: skyrocketed 388.33% in 2023, then tumbled 538.64% in 2025.
  • 60 Degrees Pharmaceuticals' Profit After Tax stood at -$1.7 million in 2022, then dropped by 20.29% to -$2.0 million in 2023, then fell by 1.4% to -$2.0 million in 2024, then dropped by 13.56% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Profit After Tax are -$2.3 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.9 million (Q1 2025).